CM
SLNO

Castleark Management’s Soleno Therapeutics SLNO Stock Holding History

Castleark Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-34,840
Closed -$2.92M – 326
2025
Q2 		$2.92M Buy
+34,840
New +$2.61M 0.09% 164

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Castleark Management's SLNO Position: Q3 2025 in Review

Castleark Management sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 34,840 shares — an estimated $2.92M sold.

Castleark Management first reported a position in SLNO in Q2 2025 and held it in 1 quarter. The position peaked at $2.92M in Q2 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Castleark Management reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Castleark Management sold 34,840 Soleno Therapeutics shares in Q3 2025, an estimated $2.92M.
  • Castleark Management first reported a position in Soleno Therapeutics in Q2 2025 and held it in 1 quarter.
  • Castleark Management's Soleno Therapeutics position peaked at $2.92M in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Castleark Management's 13F filing for Q3 2025, filed 17 Nov 2025.